Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07266857

Impact of an e-Bug Educational Intervention on HPV Vaccine Uptake in Middle School Students

This study is a non-interventional observational pilot analysis assessing the possible impact of an educational programme (e-Bug) on parental consent and HPV vaccination uptake during the 2023-2024 and 2024-2025 national school-based HPV vaccination campaigns in France. The study focuses on one middle school in the Alpes-Maritimes department where teachers and the school nurse had been previously trained on HPV and used e-Bug educational resources in class as part of routine health education. No research-related intervention was conducted, and the educational programme was not introduced or modified for the purpose of the study. Only aggregated and anonymised vaccination data were used. These data were routinely collected by the Regional Health Agency (ARS PACA) as part of the national vaccination programme and transmitted for analysis. Aggregated data from the pilot school were compared with departmental-level outcomes to describe whether an upstream educational approach may be associated with improved parental acceptance and higher HPV vaccination coverage. This study aims to contribute to the understanding of educational determinants of vaccine uptake in a real-life school setting without involving any participant recruitment or individual data collection.

Recruiting

Interested in participating?

Request Info

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • No individual participants are enrolled. The study uses only aggregated, anonymised vaccination data routinely collected by ARS PACA

Exclusion criteria

  • Not applicable. No individual-level inclusion or exclusion criteria are defined, as no participants are enrolled.

Treatment and study plan

Consent for HPV vaccination

Other

Consent for HPV vaccination

Primary outcomes

  1. HPV vaccination uptake (1st and 2nd doses) in the pilot school compared with departmental data

    Time frame: From (start of 2023-2024 HPV vaccination campaign) to(end of 2024-2025)

    e-Bug educational programme

Secondary outcomes

  1. Parental consent rate (acceptability)

    Time frame: From (start of 2023-2024 HPV vaccination campaign) to(end of 2024-2025)

    Aggregated proportion of parents providing positive consent for HPV vaccination in the pilot school, compared with aggregated departmental consent rates collected by ARS PACA during the 2023-2024 and 2024-2025 school-based campaigns.

  2. Response rate (return of vaccination authorisation forms)

    Time frame: From (start of 2023-2024 HPV vaccination campaign) to(end of 2024-2025)

    Aggregated rate of returned parental authorisation forms (regardless of response: yes/no) in the pilot school compared with departmental response rates.

Study contacts

Contact information is provided by the study sponsor or research team.

Laure Hermet

CONTACT

[email protected]

0492039007

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nice

Other

Registry information

Official study title

Pilot Observational Comparative Study Evaluating the Impact of the e-Bug Educational Programme on Parental Consent and HPV Vaccination Coverage During the National School-Based Vaccination Campaign in a Middle School in the Alpes-Maritimes

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Dec 5, 2025
Registry last updated
Dec 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.